Condition
Systemic Scleroderma clinical trials and research
As of November 12, 2026, Find a Trial lists 5 Systemic Scleroderma clinical trials that are recruiting, at sites in 4 countries (most in United States (2), France (2), Australia (1)). By phase: Phase 1/2 (1), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 4Countries
Newest Systemic Scleroderma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| CR-402 treatment for refractory autoimmune disease | Phase 1/2 | Nedlands, Western Australia | Recruiting | Aug 21, 2026 |
| Familial systemic scleroderma (scleroderma that runs in families) | — | Strasbourg | Recruiting | Jan 15, 2026 |
| Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies | — | Strasbourg | Recruiting | Nov 26, 2025 |
| SFDI imaging to measure skin fibrosis in diffuse cutaneous scleroderma | — | Boston, Massachusetts | Recruiting | Jul 29, 2025 |
| Using nivolumab to treat patients with autoimmune disorders and advanced cancer | Phase 1 | Birmingham, Alabama and 51 other locations | Recruiting | Jan 25, 2019 |
All recruiting trials (5)
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Familial systemic scleroderma (scleroderma that runs in families)
This project will look at adults with systemic scleroderma who have a first-degree relative with the disease to try to find genetic and molecular markers that predict progression and point to new treatment targets.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
-
SFDI imaging to measure skin fibrosis in diffuse cutaneous scleroderma
This study tries SFDI, a painless light-based imaging method, to measure skin thickening in people with early diffuse cutaneous scleroderma.
-
Using nivolumab to treat patients with autoimmune disorders and advanced cancer
This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.
Related topics
Quick answers
How many Systemic Scleroderma clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (2 trials), France (2 trials), Australia (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1/2: 1, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.